About
Rafael Rosengarten is CEO and co-founder of Genialis, the RNA biomarker company, building…
Articles by Rafael
-
Confronting Data Bias in Healthcare and the World
Confronting Data Bias in Healthcare and the World
By Rafael Rosengarten
Activity
-
Off to Alaska with my Dad!!! Can’t wait to catch some monster King Salmon and Halibut!!! This is 40, this is 70!! #FatherSonTrip
Off to Alaska with my Dad!!! Can’t wait to catch some monster King Salmon and Halibut!!! This is 40, this is 70!! #FatherSonTrip
Liked by Rafael Rosengarten
-
Hello from Oxford! 🌍 Genialis' data scientists Eva Lavrenčič, Lea Vohar, and Jurij Nastran recently attended the MLx Health & Bio summer school at…
Hello from Oxford! 🌍 Genialis' data scientists Eva Lavrenčič, Lea Vohar, and Jurij Nastran recently attended the MLx Health & Bio summer school at…
Liked by Rafael Rosengarten
-
“[Genialis’] approach begins with biology, and it is very different from other companies," said Debiopharm's Head of Translational Medicine Carolina…
“[Genialis’] approach begins with biology, and it is very different from other companies," said Debiopharm's Head of Translational Medicine Carolina…
Liked by Rafael Rosengarten
Experience & Education
-
Genialis
View Rafael’s full experience
See their title, tenure and more.
or
Languages
-
Spanish
-
More activity by Rafael
-
Today 𝟱𝟴% of Genialis colleagues run regularly. 🏃♀️ But just 3 months ago, the number was closer to 𝟭𝟴%. How did that change so…
Today 𝟱𝟴% of Genialis colleagues run regularly. 🏃♀️ But just 3 months ago, the number was closer to 𝟭𝟴%. How did that change so…
Liked by Rafael Rosengarten
-
Happy to share this interesting article from Sifted featuring our Debiopharm Innovation Fund's strategic investments in Genialis and Nucleai! Their…
Happy to share this interesting article from Sifted featuring our Debiopharm Innovation Fund's strategic investments in Genialis and Nucleai! Their…
Liked by Rafael Rosengarten
-
https://lnkd.in/ep35AuAc 🤔Ever wondered what it feels like to have a strategic investor at the table ? Go and find out in this latest piece from…
https://lnkd.in/ep35AuAc 🤔Ever wondered what it feels like to have a strategic investor at the table ? Go and find out in this latest piece from…
Liked by Rafael Rosengarten
-
Recursion's stock popped today on news that the biotech company announced guidance on seven clinical readouts at its investor day, as well as updates…
Recursion's stock popped today on news that the biotech company announced guidance on seven clinical readouts at its investor day, as well as updates…
Liked by Rafael Rosengarten
-
#WhatsUpWednesday this week features The Alliance for Artificial Intelligence in Healthcare (AAIH) Vice Chair Maria Luisa Pineda, PhD. and her…
#WhatsUpWednesday this week features The Alliance for Artificial Intelligence in Healthcare (AAIH) Vice Chair Maria Luisa Pineda, PhD. and her…
Liked by Rafael Rosengarten
-
AI is evolving quickly, and many feel a sense of urgency. Clinicians must have a strong basis to trust that an AI solution will improve patient care…
AI is evolving quickly, and many feel a sense of urgency. Clinicians must have a strong basis to trust that an AI solution will improve patient care…
Liked by Rafael Rosengarten
-
Excited to see our first molecule get to the clinic!
Excited to see our first molecule get to the clinic!
Liked by Rafael Rosengarten
-
97% of clinical trials for cancer therapies fail — but perhaps AI could help. The industry is turning to AI to find novel biomarkers which could…
97% of clinical trials for cancer therapies fail — but perhaps AI could help. The industry is turning to AI to find novel biomarkers which could…
Liked by Rafael Rosengarten
-
💡 Ever wondered what it means to have a strategic investor at the table? We're thrilled to share this article from Sifted featuring our Innovation…
💡 Ever wondered what it means to have a strategic investor at the table? We're thrilled to share this article from Sifted featuring our Innovation…
Liked by Rafael Rosengarten
-
I have given a lot of talks over the years but my most popular one is one a very unpopular topic. The topic of how to shut down a company. Besides a…
I have given a lot of talks over the years but my most popular one is one a very unpopular topic. The topic of how to shut down a company. Besides a…
Liked by Rafael Rosengarten
-
It is pretty insane. The company just raised $372M Series D to apply LLM/AI models for developing in-licensed drugs. Backed by Sanofi and a16z…
It is pretty insane. The company just raised $372M Series D to apply LLM/AI models for developing in-licensed drugs. Backed by Sanofi and a16z…
Liked by Rafael Rosengarten
-
There are as many KRASi drug candidates as Wimbledon 🎾 tennis players right now. Sounds like a lot. But given the high failure rate of clinical…
There are as many KRASi drug candidates as Wimbledon 🎾 tennis players right now. Sounds like a lot. But given the high failure rate of clinical…
Liked by Rafael Rosengarten
People also viewed
-
Naheed Kurji
Connect -
Cédric Odje
Investor | Supporting Innovators Driving Positive Impact on Patient Care and Health Outcomes.
Connect -
Maria Luisa Pineda, PhD.
Connect -
James Zanewicz, JD, LLM, RTTP
Connect -
Prapti Koirala
Connect -
Adam Roose
Vice President, Cell & Gene Commercial Strategy at Adjuvant Partners
Connect -
Andrea Vuturo
Integrated Marketing & External Communications Strategist
Connect -
Angeli Möller, PhD
Connect -
Stacie Calad-Thomson
Connect -
Mida Pezeshkian, PhD
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More